Applied BioMedicine: Biomarkers
Caprion’s Applied BioMedicine group applies CellCarta® to comprehensively profile proteins in plasma or other accessible fluids from humans or animal models under various conditions (e.g., healthy, disease, drug-treated disease). Their goal is to deliver biomarkers that both improve disease diagnosis and enhance pre-clinical /clinical decision-making. The Group has extensive experience and demonstrated biomarker discovery capabilities with human and animal model plasma samples, in both pre-clinical and clinical stage compounds, and across a wide spectrum of disease areas including inflammation, cancer, pain, diabetes, Alzheimer’s and cardiovascular diseases
It is a process that has been validated through multiple and recurring partnerships, and it is a solution trusted by leading biotech and pharmaceutical companies. Several biomarker projects have been completed over the past three years for AstraZeneca, Wyeth, Pfizer and Boehringer Ingelheim, Berlex, ICOS and most recently collaborations were initiated with Centorcor and Vertex.
CellCarta® is ideally suited to deliver valuable insights for its internal programs and its partners that:
- Improve clinical compound selection by ranking pre-clinical candidates improving go/no-go decision-making;
- Improve disease diagnosis and monitoring;
- Improve criteria for clinical trial patient enrollment or stratification;
- Provide earlier determination of drug efficacy and/or toxicity;
- Increases understanding of the mechanisms of action;
- Improve product positioning and differentiation from competitive products.
Caprion has also undertaken two internal plasma biomarker discovery programs on human plasma clinical samples in the area of Alzheimer’s disease and Hypertension.
Applied BioMedicine: Diagnostics
In combining one or more of the CellCarta® applications, Caprion offers prospective partners multiple sources of input in the identification of proteins as targets as candidates for in vitro diagnostic applications.
The figure below outlines the potential sources of data for the generation of in vitro diagnostic target candidates, using CellCarta® as the final common endpoint.
